Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1292902
                    [Title] => New Biologic Drug Is Targeted Treatment for Ovarian Cancer
                    [Summary] => 
Researchers have announced the development of a new biologic drug targeted to treat ovarian cancer. Its design could improve the treatment and survival statistics for some women suffering from this type of malignancy.

                    [DatePublished] => 2014-02-21 07:00:05
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 1788586
                    [AuthorName] => Vonda J. Sines
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => http://img834.imageshack.us/img834/1294/46r7.jpg
                )

            [1] => Array
                (
                    [ArticleID] => 850063
                    [Title] => Women urged to start pelvic exams at 40
                    [Summary] => 
Women usually experience pelvic discomfort or bloating at different periods of their life. Increased abdominal girth that makes clothes fit tighter around the waist is a common condition that many women ignore, or just attribute to eating too much or aging.
                    [DatePublished] => 2012-09-18 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 743585
                    [Title] => Roche launches  drug for advanced  ovarian cancer
                    [Summary] => 
Pharmaceutical company Roche recently launched an important milestone making its targeted therapy bevacizumab available for a disease where few treatment advances have been seen in over two decades.
                    [DatePublished] => 2011-11-03 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 742896
                    [Title] => First-line treatment for advanced ovarian cancer
                    [Summary] => 
Pharmaceutical company Roche recently launched an important milestone making its targeted therapy bevacizumab available for a disease where few treatment advances have been seen in over two decades.
                    [DatePublished] => 2011-11-01 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 731565
                    [Title] => Treatment for advanced ovarian  cancer receives positive opinion
                    [Summary] => 
BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.
                    [DatePublished] => 2011-09-29 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 701306
                    [Title] => Researchers analyze gene changes in ovarian cancer
                    [Summary] => 
Researchers analyzing the genetic makeup of ovarian cancer tumors have found a gene mutation that is surprisingly frequent, suggesting it plays a key role in driving the cancer.
                    [DatePublished] => 2011-07-01 02:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => 
                    [SectionUrl] => 
                    [URL] => 
                )

            [6] => Array
                (
                    [ArticleID] => 696213
                    [Title] => Roche drug halves risk of disease worsening in women with recurrent ovarian cancer
                    [Summary] => 
Roche recently announced the results from OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of bevacizumab alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.
                    [DatePublished] => 2011-06-16 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [7] => Array
                (
                    [ArticleID] => 685871
                    [Title] => CA 125 plus ultrasound detects early ovarian ca
                    [Summary] => 
Large-scale screening for ovarian cancer with a combination of transvaginal ultrasound and cancer antigen 125 is a feasible strategy that can accurately identify early cancers, a large UK trial of almost 203,000 women concluded.
                    [DatePublished] => 2011-05-15 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [8] => Array
                (
                    [ArticleID] => 676897
                    [Title] => IVF regimen linked to ovarian cancer risk
                    [Summary] => 
Ovarian stimulation for in vitro fertilization was linked to an increased risk of ovarian cancer 15 years later in a large cohort study that followed thousands of women in the Netherlands.
                    [DatePublished] => 2011-04-17 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [9] => Array
                (
                    [ArticleID] => 657719
                    [Title] => Treatment helps women with ovarian cancer live significantly longer
                    [Summary] => 
Roche announced this week that OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of bevacizumab alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.
                    [DatePublished] => 2011-02-17 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

OVARIAN

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1292902
                    [Title] => New Biologic Drug Is Targeted Treatment for Ovarian Cancer
                    [Summary] => 
Researchers have announced the development of a new biologic drug targeted to treat ovarian cancer. Its design could improve the treatment and survival statistics for some women suffering from this type of malignancy.

                    [DatePublished] => 2014-02-21 07:00:05
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 1788586
                    [AuthorName] => Vonda J. Sines
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => http://img834.imageshack.us/img834/1294/46r7.jpg
                )

            [1] => Array
                (
                    [ArticleID] => 850063
                    [Title] => Women urged to start pelvic exams at 40
                    [Summary] => 
Women usually experience pelvic discomfort or bloating at different periods of their life. Increased abdominal girth that makes clothes fit tighter around the waist is a common condition that many women ignore, or just attribute to eating too much or aging.
                    [DatePublished] => 2012-09-18 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 743585
                    [Title] => Roche launches  drug for advanced  ovarian cancer
                    [Summary] => 
Pharmaceutical company Roche recently launched an important milestone making its targeted therapy bevacizumab available for a disease where few treatment advances have been seen in over two decades.
                    [DatePublished] => 2011-11-03 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 742896
                    [Title] => First-line treatment for advanced ovarian cancer
                    [Summary] => 
Pharmaceutical company Roche recently launched an important milestone making its targeted therapy bevacizumab available for a disease where few treatment advances have been seen in over two decades.
                    [DatePublished] => 2011-11-01 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 731565
                    [Title] => Treatment for advanced ovarian  cancer receives positive opinion
                    [Summary] => 
BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.
                    [DatePublished] => 2011-09-29 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 701306
                    [Title] => Researchers analyze gene changes in ovarian cancer
                    [Summary] => 
Researchers analyzing the genetic makeup of ovarian cancer tumors have found a gene mutation that is surprisingly frequent, suggesting it plays a key role in driving the cancer.
                    [DatePublished] => 2011-07-01 02:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => 
                    [SectionUrl] => 
                    [URL] => 
                )

            [6] => Array
                (
                    [ArticleID] => 696213
                    [Title] => Roche drug halves risk of disease worsening in women with recurrent ovarian cancer
                    [Summary] => 
Roche recently announced the results from OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of bevacizumab alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.
                    [DatePublished] => 2011-06-16 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [7] => Array
                (
                    [ArticleID] => 685871
                    [Title] => CA 125 plus ultrasound detects early ovarian ca
                    [Summary] => 
Large-scale screening for ovarian cancer with a combination of transvaginal ultrasound and cancer antigen 125 is a feasible strategy that can accurately identify early cancers, a large UK trial of almost 203,000 women concluded.
                    [DatePublished] => 2011-05-15 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [8] => Array
                (
                    [ArticleID] => 676897
                    [Title] => IVF regimen linked to ovarian cancer risk
                    [Summary] => 
Ovarian stimulation for in vitro fertilization was linked to an increased risk of ovarian cancer 15 years later in a large cohort study that followed thousands of women in the Netherlands.
                    [DatePublished] => 2011-04-17 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [9] => Array
                (
                    [ArticleID] => 657719
                    [Title] => Treatment helps women with ovarian cancer live significantly longer
                    [Summary] => 
Roche announced this week that OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of bevacizumab alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.
                    [DatePublished] => 2011-02-17 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest